In the face of the constantly mutated Omiljun strain, in addition to inoculation and strengthening needles, how do we control it?

According to WHO's latest real-time statistics, the cumulative number of confirmed COVID-19 cases

This week, two vaccines were included in emergency use

On the evening of September 4, CanSino issued an announcement on the Shanghai Stock Exchange that the company's recombinant novel coronavirus vaccine for inhalation (Ad5-nCoV for inhalation) was recommended by the National Health Commission, and the State Drug Administration organized and agreed to be included in emergency use as a reinforcing

The People's Daily health client combed and found that so far, China has 9 new crown vaccines that can be used

In terms of treatment, The small molecule new crown oral drug azifed and the domestic new crown neutralizing antibody amphavir monoclonal antibody combination therapy independently developed in China have been put into clinical application

With so many "weapons" in hand, in the face of the upcoming third winter, what progress will be made in the prevention and control of the new crown?

Visitors experience inhaled vaccine equipment at the Hainan Bojian Meeting, CanSino Bio WeChat public account map

CanSino inhalation with recombinant novel coronavirus vaccine in

CanSino inhalation with recombinant novel coronavirus vaccine in

More than 820 million people in China have completed boosted immunization

According to data released by the National Health Commission, as of August 9 this year, 31 provinces (autonomous regions and municipalities directly under the Central Government) and the Xinjiang Production and Construction Corps have reported a cumulative total of more than 3.

The number of people who have completed the full vaccination reached 1.

In the local epidemic situation in China, BA.

Globally, 19.

Two COVID-19 vaccines were urgently approved to facilitate sequential vaccination

At the beginning of September, the State Food and Drug Administration intensively approved the recombinant novel coronavirus fusion protein vaccine and the inhaled new crown vaccine for emergency use

The results of the phase III clinical trial of V-01 sequential strengthening showed that the absolute protective power of the V-01 sequential strengthening group compared with the control group of 2-dose inactivated vaccine reached 61.

The V-01 sequential strengthening group had an absolute protective power of 61.

As a booster needle, higher levels of humoral and cellular immunity can be activated, with the potential to allow the virus to be cleared in a shorter period of time while increasing the duration of the vaccine's protective potency

Oral drugs and neutralizing antibodies are already in clinical use, and more drugs are being developed

Oral drugs and neutralizing antibodies are already in clinical use, and more drugs are being developed

On July 25, 2022, Azfding was approved by the State Food and Drug Administration for the treatment of adult patients

In July, Fosun Pharmaceutical Industry entered into an agreement with Real Bio to establish a strategic cooperation
on matters such as joint development and exclusive commercialization by Fosun Pharmaceutical Industry.
According to First Finance, Wu Yifang, chairman of Fosun Pharma, said that the data of Azfedine in the real world has not yet been fully formed, and as of now, in terms of medication, the overall safety and tolerance are good
.
"The overall effectiveness of the drug and the prevention and control situation will need to wait for a while
.
"

Overall safety and tolerance is good
.
"The overall effectiveness of the drug and the prevention and control situation will need to wait for a while.
"

Ambavir monoclonal antibody / romimab combination therapy arrived in Guangdong, Tengsheng Bo medicine for the picture
.

In addition, in July this year, China's first new crown neutralizing antibody ampavirinumab / romimab combination therapy was commercially listed
in China.
Clinical studies have shown that the drug can reduce the risk of hospitalization and death in patients with COVID-19 who are clinically at high risk by 80%.

According to the news released by Tengsheng Bo Pharmaceutical, from June to December 2021, the company donated nearly 3,000 copies of ambavir monoclonal antibody/romizumab drug to treat nearly 1,000 patients
.

The drug can reduce the risk of hospitalization and death in patients with COVID-19 whose clinical progression is at high risk by 80%

Zhang Linqi, a professor at Tsinghua University School of Medicine, previously said in an interview with the Global Times that small molecule drugs and large molecule neutralizing antibody drugs have their own advantages: small molecule drugs have low production costs, and oral methods are simple and convenient; Although the production cost of macromolecular neutralizing antibody drugs is high, because it originates from the body's own immune response, it can quickly enhance immunity and exert antiviral effects
after entering the human body.

Small molecule drugs have low production costs and simple and convenient oral administration; Although the production cost of macromolecular neutralizing antibody drugs is high, because it originates from the body's own immune response, it can quickly enhance immunity and exert antiviral effects after entering the human body

In addition, according to Xinhua News Agency, there are currently a number of new crown treatment drugs in China that are in different stages of research and development, and some drugs have been carried out in phase III clinical trials
at home and abroad.
According to the relevant person in charge of the scientific research team of the joint prevention and control mechanism of the State Council, the current research and development of new crown therapeutic drugs mainly revolves around three technical routes: blocking the virus from entering the cell, inhibiting virus replication, and regulating the human immune system, and China has deployed
on these technical routes.

At present, the research and development of new crown therapeutic drugs mainly revolves around blocking the virus from entering the cell, inhibiting virus replication, and regulating the human immune system
.